Hospital group Sanford Health has invested $20 million in InGeneron to support clinical trials of a stem cell regenerative medicine.

Sanofi and Regeneron have taken a deeper dive into phase 3 data on hotly tipped atopic dermatitis drug dupilumab.

Sanofi has paid €120 million upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against RSV.

Arix Bioscience has teamed up with Takeda Ventures to create and grow biotechs.

Advaxis has licensed its antigen delivery technology for use in Sellas’ cancer immunotherapy.

Almac Discovery and the Royal College of Surgeons in Ireland have teamed up to research the effect of ALM201 on cancer stem cells.

Ferring Pharmaceuticals is funding development of a long-duration peptide drug based on Foresee’s delivery technology.

Johnson & Johnson has unveiled a clutch of deals intended to grow its presence in the microbiome sector.

Ophthotech has started a search for ophthalmic drugs, pipeline prospects and technologies it can rebuild its business around.